Chemours Co. Files 8-K: Material Agreement & Financial Obligation

TL;DR

Chemours signed a big deal and took on new debt. Details to follow.

AI Summary

On November 27, 2024, The Chemours Company (Chemours) entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The specific details of the agreement and the financial obligations are not fully disclosed in this initial report.

Why It Matters

This filing signals a significant new agreement and potential financial commitment for Chemours, which could impact its future operations and financial health.

Risk Assessment

Risk Level: medium — The entry into a material definitive agreement and creation of financial obligations inherently carry risks that are not yet fully detailed in this filing.

Key Players & Entities

• The Chemours Company (company) — Registrant
• Chemours (company) — Registrant (shortened name)
• November 27, 2024 (date) — Date of Report and Earliest Event

FAQ

Key Financial Figures

• $0.01 — nge on Which Registered Common Stock ($0.01 par value) CC New York Stock Exchan
• $600,000,000 — he private offering (the "Offering") of $600,000,000 aggregate principal amount of the Compa

Filing Documents

• cc-20241127.htm (8-K) — 62KB
• cc-ex4_2.htm (EX-4.2) — 1KB
• cc-ex4_2.pdf (EX-4.2) — 862KB
• cc-ex99_1.htm (EX-99.1) — 21KB
• img15408389_0.jpg (GRAPHIC) — 37KB
• img172710962_0.jpg (GRAPHIC) — 35KB
• 0000950170-24-131547.txt ( ) — 1530KB
• cc-20241127.xsd (EX-101.SCH) — 29KB
• cc-20241127_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. The information set forth in Item 8.01 of this Current Report on Form 8-K regarding the 2020 Base Indenture (as defined below) and the 2024 Third Supplemental Indenture (as defined below) is incorporated herein by reference.

03

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 8.01 of this Current Report on Form 8-K regarding the Notes is incorporated herein by reference.

01

Item 8.01 Other Events. On November 27, 2024, The Chemours Company (the "Company") closed the private offering (the "Offering") of $600,000,000 aggregate principal amount of the Company's 8.000% Senior Notes due 2033 (the "Notes"), pursuant to the Purchase Agreement (the "Purchase Agreement"), dated as of November 13, 2024, by and among the Company, the guarantors named therein (the "Guarantors") and Goldman Sachs & Co. LLC, as representative of the several initial purchasers named therein. The Notes were issued pursuant to the Indenture, dated as of November 27, 2020 (the "2020 Base Indenture"), between the Company and Deutsche Bank Trust Company Americas, as successor trustee to U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank Trust Company), as trustee (the "Trustee"), as supplemented by the Third Supplemental Indenture setting forth the terms of the Notes, dated as of November 27, 2024, among the Company, the guarantors named therein and the Trustee (the "2024 Third Supplemental Indenture" and together with the 2020 Base Indenture, the "Indenture"). The net proceeds of the Offering are expected to be used to redeem all of the Company's outstanding euro-denominated 4.000% Senior Notes due 2026, which is expected to be 440,810,000, plus accrued and unpaid interest to, but excluding, the date of redemption, and the remainder of the net proceeds for general corporate purposes. The Notes were offered in the United States to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), outside the United States pursuant to Regulation S under the Securities Act and to institutional accredited investors (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act) in reliance on a private placement exemption from registration under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act. The Notes have not been and will not be registered under t

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 4.1 Indenture, dated as of November 27, 2020, among The Chemours Company and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to The Chemours Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on November 27, 2020). Exhibit 4.2 Third Supplemental Indenture, dated as of November 27, 2024, among The Chemours Company, the guarantors party thereto and Deutsche Bank Trust Company Americas, as trustee Exhibit 4.3 Specimen 8.000% Senior Notes Due 2033 (included in Exhibit 4.2) Exhibit 99.1 Press release dated as of November 27, 2024 issued by the Chemours Company Exhibit 104 Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THE CHEMOURS COMPANY By: /s/ Shane Hostetter Shane Hostetter Senior Vice President, Chief Financial Officer Date: November 27, 2024

View Full Filing

View this 8-K filing on SEC EDGAR